-
-
-
Hyundai MOBIS moves forward with its new 'Move Improved' campaign
With a tagline \'Move Improved\',advanced mobility technologies are introduced in a joyful and relatable story of driving experience.
Hyundai Mobis / 01-26
-
-
-
-
Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors
SINGAPORE and PHILADELPHIA,Jan. 24,2025-- Nuevocor,an IND-stage biotechnology company dedicated to developing functional cures to treat cardiomyopathies with aberrant mechanobiology,today announces t
Nuevocor / 01-26
-
-
-
-
“YepZan!” & Huawei Cloud Launch AI-Powered Arabic Language Learning Tools in Middle East
“YepZan!” & Huawei Cloud Launch AI-Powered Arabic Language Learning Tools in Middle East
-
-
-
-
Alpha Stock Investment Training Center ASITC Announces Ambitious 2025 Initiatives
Alpha Stock Investment Training Center ASITC Announces Ambitious 2025 Initiatives
-
-
-
-
Promotion of ‘Haisi Port Co-operation Forum’ Held in London
Golden Age Media, London, January 14,, Ningbo Zhoushan Port Group in London, England, held a ‘Haisi Port Cooperation Forum (MPF2025)’ promotion activities, the Chinese Embassy in London, Zhejiang Provincial Seaport Group, Ningbo Zhoushan Port Group, the British shipping, the media and other guests more than 70 people attended the promotion.
-
-
-
-
AIMA Ebike Unveils High-Performance eBike Lineup at CES 2025: Quality, Precision, and Innovation Redefine Urban Mobility
LAS VEGAS,Jan. 18,2025--AIMA Ebike has taken a bold step into the future of urban mobility at CES 2025,unveiling a revolutionary new lineup of eight eBikes that combine advanced technology,superior pe
-
-
-
-
The Spring Festival Celebration: Explore Beautiful Yunnan
KUNMING,China,Jan. 20,2025-- Yunnan Innyo Co.,Ltd.,in collaboration with @visityunnan,is excited to announce an engaging event inviting videography enthusiasts from around the world to capture the bea
-
-
-
-
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI,Jan. 21,2025--YolTech Therapeutics,a clinical-stage gene editing company dedicated to delivering lifelong cures,announced the initiation of a clinical trial for YOLT-204,an investigational th
-
Current news
Newest
